Los Angeles, CA, USA, ImaginAb, Inc., a market leading global biotechnology company focused on developing next generation ImmunoPET imaging agents and therapeutic radiopharmaceuticals (RPT), is pleased to announce it has signed a new multi-year, non-exclusive supply agreement with Genmab A/S, an international biotechnology company. Under the terms of the agreement, ImaginAb will provide a non-exclusive, worldwide license to Genmab A/S to use its investigational CD8 ImmunoPET imaging technology (zirconium Zr 89 crefmirlimab berdoxam) in clinical trials. Commenting on the announcement, Ian Wilson, Chief Executive Officer of ImaginAb stated: “We are delighted to announce this new supply agreement with Genmab A/S, who, under the
The post ImaginAb Announces New Supply Agreement to Supply Genmab A/S with its Investigational CD8 ImmunoPET Agent appeared first on Pharma Mirror Magazine.
